[PDF][PDF] Long-term efficacy of anti-tumor necrosis factor agents in pediatric luminal Crohn's disease: A systematic review of real-world evidence studies
H Van Rheenen… - … , Hepatology & Nutrition, 2020 - synapse.koreamed.org
Purpose: To determine the long-term efficacy of the anti-tumor necrosis factor (TNF) agents,
infliximab (IFX) and adalimumab (ADA), in pediatric luminal Crohn's disease (CD) by …
infliximab (IFX) and adalimumab (ADA), in pediatric luminal Crohn's disease (CD) by …
Predictors of response to Infliximab in children with luminal Crohn's disease
Objective A significant proportion of patients with initial response to Inflximab (IFX),
subsequently lose response (LOR). Multicentre paediatric studies report LOR in 33% to 50 …
subsequently lose response (LOR). Multicentre paediatric studies report LOR in 33% to 50 …
Canadian association of gastroenterology clinical practice guideline for the medical management of pediatric luminal Crohn's disease
DR Mack, EI Benchimol, J Critch… - Journal of the …, 2019 - academic.oup.com
Abstract Background & Aims We aim to provide guidance for medical treatment of luminal
Crohn's disease in children. Methods We performed a systematic search of publication …
Crohn's disease in children. Methods We performed a systematic search of publication …
Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease
PC Church, J Guan, TD Walters, K Frost… - Inflammatory bowel …, 2014 - academic.oup.com
Background Infliximab induces and maintains clinical remission in children with Crohn's
disease (CD), but specifically pediatric long-term data remain sparse. Methods Patients (N …
disease (CD), but specifically pediatric long-term data remain sparse. Methods Patients (N …
Mucosal healing in paediatric patients with moderate-to-severe luminal Crohn's disease under combined immunosuppression: escalation versus early treatment
B Kang, SY Choi, HS Kim, K Kim… - Journal of Crohn's …, 2016 - academic.oup.com
Abstract Background and Aims: We aimed to compare the efficacy of combined
immunosuppression in terms of mucosal healing in paediatric patients with moderate-to …
immunosuppression in terms of mucosal healing in paediatric patients with moderate-to …
Risk Factors of Clinical Relapses in Pediatric Luminal Crohn's Disease: A Retrospective Cohort Study
S Sassine, L Djani, C Cambron-Asselin… - Official journal of the …, 2022 - journals.lww.com
METHODS: Patients younger than 18 years and diagnosed between 2009 and 2019 were
included in this retrospective cohort study. Clinical, endoscopic, histological, and laboratory …
included in this retrospective cohort study. Clinical, endoscopic, histological, and laboratory …
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre …
MME Jongsma, MA Aardoom, MA Cozijnsen… - Gut, 2022 - gut.bmj.com
Objective In newly diagnosed paediatric patients with moderate-to-severe Crohn's disease
(CD), infliximab (IFX) is initiated once exclusive enteral nutrition (EEN), corticosteroid and …
(CD), infliximab (IFX) is initiated once exclusive enteral nutrition (EEN), corticosteroid and …
Comparative effectiveness of anti-TNF in combination with low-dose methotrexate vs anti-TNF monotherapy in pediatric Crohn's disease: a pragmatic randomized trial
MD Kappelman, DA Wohl, HH Herfarth, AM Firestine… - Gastroenterology, 2023 - Elsevier
Background & Aims Tumor necrosis factor inhibitors, including infliximab and adalimumab,
are a mainstay of pediatric Crohn's disease therapy; however, nonresponse and loss of …
are a mainstay of pediatric Crohn's disease therapy; however, nonresponse and loss of …
[HTML][HTML] Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease
ES Kim, B Kang - World journal of gastroenterology, 2023 - ncbi.nlm.nih.gov
Biologic agents with various mechanisms against Crohn's disease (CD) have been released
and are widely used in clinical practice. However, two anti-tumor necrosis factor (TNF) …
and are widely used in clinical practice. However, two anti-tumor necrosis factor (TNF) …
Improved Clinical Outcomes With Early Anti-Tumour Necrosis Factor Alpha Therapy in Children With Newly Diagnosed Crohn's Disease: Real-world Data from the …
RCW Klomberg, HC van der Wal… - Journal of Crohn's …, 2024 - academic.oup.com
Abstract Background and Aims Treatment guidelines for paediatric Crohn's disease [CD]
suggest early use of anti-tumour necrosis factor alpha [anti-TNFα] in high-risk individuals …
suggest early use of anti-tumour necrosis factor alpha [anti-TNFα] in high-risk individuals …